Concert Pharmaceuticals Inc (CNCE) Given Average Recommendation of “Hold” by Analysts

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has received a consensus recommendation of “Hold” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $28.50.

A number of equities analysts have weighed in on CNCE shares. ValuEngine upgraded Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 3rd. Mizuho reiterated a “buy” rating and set a $27.00 price objective on shares of Concert Pharmaceuticals in a research note on Tuesday, April 10th. Zacks Investment Research upgraded Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Tuesday, May 1st. HC Wainwright lifted their price objective on Concert Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, May 4th. Finally, BidaskClub lowered Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 17th.

In other Concert Pharmaceuticals news, COO Nancy Stuart sold 31,418 shares of Concert Pharmaceuticals stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $17.87, for a total transaction of $561,439.66. Following the completion of the transaction, the chief operating officer now owns 116,085 shares in the company, valued at approximately $2,074,438.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 9.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. raised its stake in shares of Concert Pharmaceuticals by 679.4% during the 2nd quarter. Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 5,496 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new position in shares of Concert Pharmaceuticals during the 4th quarter valued at about $164,000. MetLife Investment Advisors LLC purchased a new position in shares of Concert Pharmaceuticals during the 4th quarter valued at about $232,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Concert Pharmaceuticals during the 1st quarter valued at about $197,000. Finally, Tyers Asset Management LLC acquired a new stake in shares of Concert Pharmaceuticals during the 1st quarter valued at about $236,000. Institutional investors and hedge funds own 74.11% of the company’s stock.

Concert Pharmaceuticals traded up $0.06, reaching $16.22, during midday trading on Friday, MarketBeat Ratings reports. The stock had a trading volume of 258,669 shares, compared to its average volume of 279,019. The firm has a market capitalization of $378.08 million, a price-to-earnings ratio of 3.98 and a beta of 1.09. Concert Pharmaceuticals has a 52-week low of $13.57 and a 52-week high of $30.71.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.39. The company had revenue of $10.48 million during the quarter. Concert Pharmaceuticals had a negative return on equity of 23.57% and a net margin of 67.71%. equities analysts predict that Concert Pharmaceuticals will post -2.21 earnings per share for the current year.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Featured Article: Growth Stocks

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply